The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever
ballot for industrial action.
The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action.
The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to
lawfully take industrial action, means trade unions should test members' strength of feeling before balloting."
"Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of
eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'."
The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA
has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.
In a recent report released by the Company Chemists' Association (CCA), data from the NHS Pharmacy First service indicates a substantial uptake and
positive impact on patient care just two months after its launch.
The CCA's findings shed light on the service's efficacy in meeting patient needs and its potential to alleviate pressure on General Practices (GPs) within the NHS.
According to the report, over 90,000 Pharmacy First consultations were conducted solely by CCA members within the initial two-month period.
Impressively, 88 per cent of these consultations, totaling 81,627, were deemed eligible for NHS-funded care indicating a significant demand for the service among
patients.
In the first month, the data revealed that more than 90 per cent of eligible patients received necessary care directly through Pharmacy First, bypassing the
need for further referral.
The Health Education England (HEE) has allocated £440,000 to help upskill pharmacists working in adult critical care across England.
UK Clinical Pharmacy Association (UKCPA) has confirmed with HEE that UKCPA critical care courses meet the criteria for this funding, for courses that complete before
31 March 2023.
"The funding is expected to exceed demand and so it is likely that bids for these UKCPA courses will be approved by HEE, as they meet the learning outcomes in the
new RPS/UKCPA/FICM specialist critical care curricula (in development)," said UKCPA.
Department of Health and Social Care (DHSC) has implemented a process to roll over certain concessionary prices to the following month.
From May 2023, the roll over process will apply to any products where agreement is reached on the final prices granted by DHSC for any price concession requests
submitted late in the month (on or after the 23rd of the month) by Community Pharmacy England.
Community Pharmacy England said: "As part of the Year 4 & 5 funding settlement for community pharmacy, it was agreed that an urgent review of the price concession
setting system would take place."
It has been working with DHSC to determine improvements to the price concession system.
Community Pharmacy England said: "Pharmacy owners (members) will be able to see the lines that have rolled over on our price concessions page here. Please note
any rolled over prices can be adjusted upwards if we receive reports from our members to indicate suppliers' selling prices have increased. The review can be
requested at any point during the month."
The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups.
The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms.
Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided.
Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams
are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.
NHS England has urged women to accept cervical screening invites to make it possible to eliminate the disease within the next two decades.
Screening using a highly effective test helps detect human papillomavirus (HPV), which is responsible for over 99 per cent of all cervical cancers.
Sadly, three in ten of those eligible for screening do not take up the potentially life-saving offer, as shown by the NHS Cervical Screening Programme,
England 2022-2023 annual report.
The report, published by NHSE on Thursday, showed that a total of 4.62 million women aged 25 to 64 for cervical screening was invited to book an appointment
in 2022-23, and 3.43 million attended the screening.
"National Accreditation Board for Hospitals and Healthcare Providers" placed guidelines to those patients enrolled into Central and State government hospitals as well as the patients in Ayurvedic hospitals will be eligible for the health coverage.
Such policies will help to attract more people towards the ancient Ayurvedic healthcare practices.
Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
Covid-19 booster jab can now be administered sooner than six months after the second dose to certain vulnerable people as guideline in the UK Health Security
Agency (UKHSA) Green Book has been updated.
With the change in the guidance, care home residents who have been given their second vaccine dose at different times will be able to be jabbed in the same session,
as long as it has been at least five months since their last dose.
It may also help with other vulnerable groups, such as housebound patients to have their flu and Covid-19 vaccines at the same time.
The move will also benefit those who are about to receive immunosuppressive treatment as they can get the booster from a minimum of four months after their second dose.
Health secretary Sajid Javid said: "This updated guidance will ensure healthcare professionals have the necessary flexibility in the booster programme, allowing more
vulnerable people to be vaccinated where it makes operational sense to do so."
Vaccines minister Maggie Throup also encouraged eligible people to book their booster jab and secure protection.
NHS England and NHS Improvement have issued the patient group direction (PGD) and national protocol for community pharmacy contractors to support flu vaccination of the frontline primary care staff.
This follows the announcement pertaining to eligibility of frontline primary care staff for NHS flu vaccinations this season.
With the release of protocol, vaccination of these staff can now be commenced as part of the service.
Contractors have to keep a manual record of the number of primary care staff they vaccinate in the service and report the same each month on the NHS Business
Services Authority's Manage Your Service (MYS) platform.
As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move.
The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six
months after their second dose, and that 16 and 17 year olds should be invited to have a second dose.
Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice.
"We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."
Majority of community pharmacies are benefiting from the use of real time exemption checking (RTEC), as per an update by the NHS Business Services Authority(NHSBSA).
RTEC allows community pharmacy teams to check digitally if their patients are eligible for free NHS prescriptions because they hold a specific exemption.
The service not only saves staff time but also reduces the use of paper, risk of infection transmission and pharmacies environmental impact.
Pharmacy contractor need to confirm their agreement to the terms of the RTEC, before it can be activated.
The National Institute for Health and Care Excellence (NICE) has recommended first new treatment - 'romosozumab' for osteoporosis for over a decade.
Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment - romosozumab - after
NICE published the final draft guidance.
Over 20,000 people could be eligible for the treatment according to the company. Clinical trial evidence showed that romosozumab (also known as EVENITY and made by
UCB) followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone.
Osteoporosis is a disease that causes bones to become thin and fragile. Many people with osteoporosis show no symptoms, but they may be at increased risk of fracture.
Osteoporosis leads to nearly 9 million fractures around the world each year, and over 300,000 people per year attend hospitals in the UK with fractures caused by
osteoporosis.
Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise.
The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa.
Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England.
Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last.
But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people.
"These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.
Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report.
Demand also has been hampered by the perception that Omicron infections are not that severe.
Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial.
Thousands of people still die from Covid-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.
'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced
non-small-cell lung cancer (NSCLC).
The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project
Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster.
NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating
advanced NSCLC with METex14 skipping gene alterations in adults.
People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England.
Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700
people in England would be eligible to receive tepotinib as either a first or second-line treatment.
Out of the 2,805 students who sat for the common registration assessment test for pharmacists this June, approximately 2,150 have passed the exam, according
to the General Pharmaceutical Council. It assesses pharmacy graduates' knowledge and skills to ensure safe and effective practice as pharmacists.
This year, the pass rate was 77 per cent, slightly lower than the 80 per cent pass rate in June 2022, where 2,147 out of 2,697 candidates cleared the assessment,
GPhC data showed.
The exam comprises a written assessment testing pharmaceutical science and pharmacy practice knowledge and a practical assessment evaluating clinical skills and
patient-facing competencies. Eligible candidates must complete an accredited pharmacy degree program and meet GPhC requirements.
The assessment is conducted jointly by the General Pharmaceutical Council and the Pharmaceutical Society of Northern Ireland.
"The assessment is a primary method for testing trainees' ability to apply knowledge and make professional judgments in pharmacy practice," said Mark Voce, Director
of Education and Standards, GPhC. "This is crucial in assuring patients and the public that they are in safe hands."
Pharmacy owners can proceed with vaccinating patients who have already scheduled their flu vaccination appointments for September, NHS England has said.
However, as announced earlier, the official rollout of the vaccination service will commence from October.
Pharmacies will receive compensation for conducting appointments in the upcoming month, NHSE stated in a letter addressed to systems, community pharmacies, and
general practices.
"Payment for vaccinations will ordinarily only be made following the service commencement date. However, we understand that some firm commitments and appointments
have already been made, so where this is the case and the patient wishes to receive flu vaccination in September, NHS England will permit payment claims to be
submitted," NHSE said.
Care home residents and staff will be eligible for the vaccine starting Oct. 2, while all other patients will commence receiving their vaccinations on Oct 7.
This news is a significant relief for pharmacy owners, as they won't have to reschedule appointments due to NHSE's one-month service delay.
Becoming a pharmacist is a rewarding and fulfilling career path. Still, many aspiring pharmacists graduate with substantial student loan debt, which can
be daunting to manage while starting their careers. However, various pharmacist loan forgiveness programs can ease this financial burden and pave the way to
debt-free living. This article will explore six pharmacist loan forgiveness programs that can help pharmacists achieve financial freedom.
Public Service Loan Forgiveness (PSLF)
According to Bankrate, the Public Service Loan Forgiveness (PSLF) program is a federal program designed to forgive the remaining balance on federal Direct Loans
after 120 qualifying monthly payments while working full-time for a qualifying employer. Pharmacists who work for non-profit organizations, government agencies,
or public health organizations may be eligible for this program.
Health Professional Shortage Areas (HPSAs) Loan Repayment Program
The Health Professional Shortage Areas (HPSAs) Loan Repayment Program encourages healthcare professionals, including pharmacists, to work in areas with a shortage
of healthcare providers. Pharmacists who commit to working in designated HPSAs for a specified period can receive loan repayment assistance.